Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: Randomised clinical trial

Lancet

Volumn 364, Issue 9449, 2004, Pages 1950-1957

  Staedke, Sarah G ^a   Mpimbaza, Arthur ^b   Kamya, Moses R ^b   Nzarubara, Bridget K ^b   Dorsey, Grant ^a   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; FANSIDAR;

ADVERSE DRUG REACTION; ANEMIA; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HEPATITIS; HUMAN; INFECTION RISK; MALARIA FALCIPARUM; MALE; MEASLES; MENTAL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; PYOMYOSITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UGANDA; VOMITING;

EID: 9644269050     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17478-3     Document Type: Article

References (33)

1. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet. 353:1999;1965-1967
2. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 64:2001;12-17
3. Kamya M, Bakyaita N, Talisuna A, Were W, Staedke SG. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health. 7:2002;1031-1041
4. Bloland PB, Ettling M. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol. 93:1999;5-23
5. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 83:1990;82-85
6. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 41:1999;301-308
7. McIntosh HM.Chloroquine or amodiaquine combined with sulfadoxine- pyrimethamine for treating uncomplicated malaria (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software, 2000.
8. Gasasira AF, Dorsey G, Nzarubara B, et al. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg. 68:2003;127-132
9. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 18:2002;458-464
10. Staedke S, Kamya M, Dorsey G, et al. Amodiaquine, sulfadoxine- pyrimethamine, and combination therapy for the treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 358:2001;368-374
11. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 360:2002;2031-2038
12. Basco L, Same-Ekobo A, Ngane V, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine- amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ. 80:2002;538-545
13. Schellenberg D, Kahigwa E, Drakeley C, et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 67:2002;17-23
14. Rwagacondo CE, Niyitegeka F, Sarushi J, et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg. 68:2003;743-747
15. Ittarat W, Pickard AL, Rattanasinganchan P, et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg. 68:2003;147-152
16. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 356:2000;297-302
17. Bloland PB, Ettling M, Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 78:2000;1374-1491
18. von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet. 355:2000;352-357
19. Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 359:2002;1365-1372
20. Dorsey G, Kamya MR, Ndeezi G, et al. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg. 62:2000;686-692
21. Kamya MR, Dorsey G, Gasasira A, et al. The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans R Soc Trop Med Hyg. 95:2001;50-55
22. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. 2003;World Health Organization, Geneva
23. WHO. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. 1996;World Health Organization, Division of Control of Tropical Diseases, Geneva
24. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg. 68:2003;133-139
25. EANMAT. The efficacy of antimalarial monotherapies, sulphadoxine- pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 8:2003;860-867
26. Goodman CA, Coleman PG, Mills AJ. Changing the first line drug for malaria treatment: cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. Health Econ. 10:2001;731-749
27. Snow RW, Eckert E, Teklehaimanot A. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol. 19:2003;363-369
28. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis. 188:2003;1231-1238
29. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 87:1993;75-78
30. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Safety. 8:1993;160-168
31. Olliaro P, Mussano P. Amodiaquine for treating malaria (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software, 2003.
32. Riberio IR, Olliaro PL. Safety of artemisinin and its derivatives. Med Trop. 58:1998;50-53
33. WHO. Assessment of the safety of artemisinin compounds in pregnancy (WHO/CDS/MAL/2003.1094: WHO/RBM/TDR/ Artemisinin/03.1). Geneva: World Health Organization, 2003.